Through new and repurposed drugs, we endeavor to answer the fundamental question: how can we overcome drug resistance without causing significant patient toxicity?
Our clinical-stage candidate GO-4 is designed to treat BRCA-mutated cancers. Our extensive preclinical and discovery-phase pipeline is designed to treat other cancers and proliferative disorders.
General Oncology is poised for growth, providing career building tools and experiences. Join us in our mission to transform lives through science.
Since 1990, founding members of General Oncology have been engaged in extensive research focused on treatments for curing cancer while mitigating toxicity in patients.
General Oncology
202 Washington Street
Suite 318
Brookline, MA 02445
© 2025 General Oncology. All Rights Reserved.